RecruitingPhase 1Phase 2NCT06902896

Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy

Safety and Efficacy of Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

43 participants

Start Date

Apr 22, 2025

Study Type

INTERVENTIONAL

Conditions

Heart Failure Dilated Cardiomyopathy (DCM)

Summary

To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method for the treatment of end-stage dilated cardiomyopathy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called FAP immunosuppressive CAR-DC for people with dilated cardiomyopathy (dcm) and heart failure. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.